Cortexyme presented new data from their Phase II/III GAIN trial of atuzaginstat in mild/moderate #Alzheimers at adpdnet meeting, showing the drug inhibited lysine gingipains, plus 30%-50% slowing in cognitive decline in high P. gigivalis load cases
Cortexyme presented new data from their P... - Cure Parkinson's
Cortexyme presented new data from their Phase II/III GAIN trial of atuzaginstat in mild/moderate Alzheimers
Read more about...
Not what you're looking for?
You may also like...
Annovis Bio Releases Promising Phase III Parkinson’s Data
https://www.globenewswire.com/news-release/2024/07/02/2907365/0/en/Annovis-Bio-Announces-New-Data-fr
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
we reached the point of unblinding the data for the PD Phase III study, we discovered an unexpected...
Encouraging results from the CureParkinsons supported Phase II clinical trial of the GLP-1R agonist Liraglutide
accumulating GLP-1R data pile
https://cureparkinsons.org.uk/2022/04/liraglutide-trial-results/...
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
2019 and contemplates starting the two year Phase III trial in October of 2019, but the video says...
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
https://twitter.com/chtzoulis/status/1498750988664156166...
Related Posts
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
Good news from Annovis (for Alzheimer's)
Benfotiamine (Fat Soluble Form Of Vitamin B1) and AD
Add Idebenone Back to my Stack?
